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Protective immunity in mice to infection with theGram-positive bacterium, Listeria
monocytogenes, is mediated by Listeria-sensitizedTcells, but expressedbymacrophages
(1) . It is known (2, 3) that protective T cells are generated progressively between
days 2 and 6 of a sublethal immunizing infection, and are lost progressively after
this time, as active immunity is replaced by immunologic memory .
However, inactivation of Listeria begins on day 2 of infection, well before active
immunity peaks, and it is associated with the accumulation of monocytes at foci
ofinfection in the liver and spleen (4) . It is generally assumed that blood monocytes
are responsible for inactivating Listeria at foci of infection, and that inactivation is
efficient only after monocytes are activated by sensitized T cells . It might be ex-
pected, therefore, that any agent that prevents monocytes from accumulating at sites
of bacterial implantation would result in failure of the host to control bacterial mul-
tiplication .
An agent with likely capacity to interfere with the focusing of blood monocytes
at infective foci in the liver and spleen is a recently described (5) mAb specific for
the type 3 complement receptor (CR3)' of murine myelomonocytic cells . This rat
mAb, designated 5C6, is specific foran epitopeof theCR3 molecule that is different
from the epitopes seen by other anti-CR3 mAbs (5) . It profoundly inhibits the ca-
pacity ofneutrophils and monocytes to emigrate from blood into peritoneal inflam-
matory exudates .
The purpose of this paper is to show that intravenous injection of5C6mAb com-
pletely prevents mice from protecting themselves against a sublethal inoculum of
Listerta . It will demonstrate that the infection-promoting action of5C6 is based on
its capacity to interfere with the accumulation of monocytes at infective foci in the
liver and spleen, thereby allowing the organism to multiply unrestrictedly in non-
phagocytic cells .
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Materials and Methods
Mice.
￿
AB6F, (AxC57BL/6) male mice were used when they were 10-12 weeks old. They
were obtained from the Trudeau Institute Animal Breeding Facility, and were known to be
free of common viral pathogens, as evidence by the result of routine screening by Charles
Rivers Professional Services, Wilmington, MA.
Bacteria.
￿
A log-phase culture ofListeria monocytogenes, strain EGD, serotype 1/2a, was grown
in Trypticase-soy broth, aliquotted in 1 ml volumes and stored at -70°C. The LDso dose
was 5 x 104 intravenously in AB6 mice. For each experiment a vial was thawed and diluted
appropriately in PBS for intravenous inoculation in a volume of 0.2 ml, or for intradermal
injection in a volume of 0 .05 ml . The immunizing dose was 2 x 103 . The organism was
enumerated in the liver, spleen, and draining lymph node by plating 10-fold serial dilutions
of homogenates of these organs on Trypticase-soy agar, and counting bacterial colonies after
incubation for 24 h at 37°C. Listeria was enumerated at the site of intradermal inoculation
in the belly by removing a 1-cm square piece of the abdominal wall, including the inoculation
site. The tissue was cut into small pieces, homogenized in a blender at 10°C, and plated as
described above. Clearance of an intravenous inoculum of Listeria from blood was followed
by taking tail blood (0 .02 ml) in heparinized capillary tubes at the times indicated, diluting
the blood appropriately in PBS, subjecting the diluted blood to ultrasound to release intracel-
lular bacteria, and plating 10-fold serial dilutions ofthe sonicate on nutrient agar as described
above.
Monoclonal Antibodies.
￿
The 5C6 mAb specific for an epitope ofthe CR3 receptor ofmouse
myelomonocytic cells was generated by a rat B cell-rat myeloma hybridoma, as described
previously (5). The mAb was purified by sodium sulphate precipitation, anion exchange,
and exclusion chromatography, and the purity of the resulting IgG2b antibody assessed as
described previously (5). The antibody was injected intravenously in a dose of 0.5 mg. The
isotype-matched control rat mAb.IC5.5H10.A11 reacts with a surface and intracellular an-
tigen restricted to murine myelomonocytic cells and immunoprecipitates a glycoprotein with
a molecular mass of 200 kD nonreduced and 97 kD when reduced (Rabinowitz, S., and H.
Rosen, unpublished observations). Sodium sulphate precipitate of ascites dialyzed into PBS
and containing 0 .5 mg of monoclonal IgG was injected intravenously in each case.
Histology.
￿
Mice were killed by cervical dislocation and perfused via the left ventricle with
10° Jo buffered formalin solution. Their livers and spleens were then removed, cut into small
pieces, and fixed for 24 h in the same buffered formalin solution. The tissue was then de-
hydrated in ethanol and embedded in glycol methacrylate (JB-4 embedding kit; Polysciences,
Inc., Warrington, PA). Sections 1-2 Am in thickness were cut with glass knives and stained
with toluidine blue. Microscopy was performed with a Nikon Microphot-Fx microscope.
Results
Intravenous Injection of5C6 Prevents Micefrom Controlling Bacterial Multiplication in their
Livers and Spleens. The first experiment involved giving 5C6 intravenously to mice
24 h after inoculating them with a sublethal number (2 x 103) of Listeria via the
same route. The rationale for giving 5C6 at 24 h into infection was to allow time
for the organism to establish foci of infection in the liver and spleen . It is known
(4) that at 24 h, sites of infection are populated predominantly by neutrophils.
It can be seen in Fig. 1 that a single 0.5-mg dose of 5C6 completely eliminated
the capacity of mice to control bacterial multiplication in their livers and spleens.
Whereas Listeria was progressively eliminated after day 3 ofinfection in control mice,
it continued to multiply log linearly in the livers and spleens of 5C6-treated mice.
The infection-promoting effect of5C6 was obvious by 24 h after injection. All treated
mice died by day 4 of infection, whereas all control mice survived. Treatment with
IC5 mAb was also infection enhancing, but to a much smaller degree. Of the five
mice kept to determine survival time, three were still alive on day 10 when the ex-6-
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FIGURE 1. Intravenous injec-
tion of 0.5 mg of 5C6 mAb on
day 1 (arrow) ofa sublethal Lis-
teria infection (5 x 103 intrave-
nously) prevented mice from
controlling Listeria multiplica-
tion in their livers (left) and
spleens (right). All 5C6-treated
mice died by day4ofinfection.
Treatment of mice with the
same quantity of IC5 mAb,
however, caused much less en-
hancement of infection and
three of five of the remaining
mice survived. Means of five
mice per group.
periment was ended. This much greater infection-enhancing effect of 5C6 will be
obvious later.
5C6 Treatment Prevents theAccumulation ofMonocytesandNeutrophils at Infective Foci and
Allows Listeria to Multiply in Norphagocytic Cells. It is known (4) that sites of Listeria
infection in the liver and spleen are populated by neutrophils during the first 24 h
of infection, and increasingly by monocytes after this time. Fig. 2 a shows the ap-
pearance in section of an infective focus in the liver of a control mouse on day 3
of aListeria immunizing infection. It canbe seen that the infective focusis populated
predominantly by mononuclear cells, none of which can be seen to contain Listeria,
because of the small total number of organisms present in the liver. Indeed, many
sections hadto be scanned, even to find infective foci. In contrast, infective foci were
very numerous in sections of 3-d infected livers of 5C6-treated mice, indicating that
Listeria had disseminated from the original sites of implantation to form additional
foci of infection. More striking was the appearance (Fig. 2 b) of individual foci of
infection in the livers of 5C6-treated mice. They were not populated by monocytes,
as in control mice, but consisted of groups of infected hepatocytes in which Listeria
hadbeen multiplyingunrestrictedly. By day4of infectionfoci ofinfection were much
more numerous and larger, and were harboring enormous numbers of Listeria . It
was obvious that infection was spreading contiguously from cell to cell, as well as
via sinusoids to distant hepatocytes.
In the spleen, Listeria normally forms infective foci in the marginal zones of the
white pulp. In control mice these sites of infection were predominantly populated
by monocytes by day 3 of infection and contained very few visible Listeria. In 5C6-
treated mice, in contrast, the white pulp was almost totally destroyed by day 3 of
infection and was replete with extracellularListeria. This will be the subjectof a forth-
coming paper(Rosen, H., S. Gordon, and R. J. North, manuscript in preparation).
It was obvious from the histological study that treatment with 5C6 made miceEXACERBATION OF MURINE LISTERIOSIS
FIGURE 2 .
￿
Plastic-embedded section of site ofbacterial infection in the liver ofacontrolmouse
(a) and the liver of a 5C6-treated mouse (6) on day 3 of infection initiated with 5 x 10 3 Listeria
intravenously. Whereas infectioe foci in controlmice typically become populated by mononuclear
cells, infectioe foci in 5C6-treated mice consist of groups of heavily infected hepatocytes with
no obvious involvement of mononuclear phagocytes . x400.totally incapable of controlling bacterial multiplication and of confiningbacteria to
original sites of implantation. Consequently, the organism was free to disseminate
from cell to cell, as well as via the blood to distant sites.
5C6Has Only a MarginalInfection-enhancingEffect ifGiven after Day 3ofInfection.
￿
It
was shown above that injecting 5C6 mAb on day 1 of a sublethal Listeria infection
rapidly converted the infection to a lethal one, apparently because of a failure by
the host to focus monocytes at sites of bacterial multiplication. It was important to
determine next whether 5C6 is capable of promoting infection if given at a stage
ofinfection when foci ofinfection are known to be already populated by monocytes,
namely, between days 3 and 6.
Fig. 3 shows that, whereasinjecting5C6 on day 1 ofinfection resulted in log linear
bacterial growth in the liverand spleen, injecting the same quantity of the antibody
on days 4or 6, when bacteria were already beinginactivated in theseorgans, caused
only a temporary promotion of infection. The former mice all died from infection,
whereas the latter all survived .
5x103 LISTERIA
FIGURE 3.
￿
5C6treatment converted asublethal
Listeria infection to a lethal one if given on day
1 of infection, but not if given on days 4 or 6.
Whereas 5C6 treatment on day 1 caused unre-
stricted log linearmultiplication of Listeria, in the
spleen and liver, 5C6 treatment on days 4 or 6
caused only a temporary increase in bacterial
growth. Only those mice treated on day 1 died
of infection. Means of five mice per group.
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5C6Does Not Inhibit the Capacity of Kupffer Cells to Remove Listeriafrom the Blood and
Inactivate It. It is known (6) that 95% of an intravenous inoculum ofListeria is cleared
by the liver, and that 50"/o or more ofthe cleared organisms are inactivated by Kupffer
cells within 8-12 h. Because Kupffer cells express very low to undetectable levels
of surface CR3 receptor (7), it was anticipated that treatment with 5C6 would not
interfere with their ability to express this preimmunity antibacterial function in the
liver.
Fig. 4 shows that intravenous injection of 5C6 mAb did not interfere with the
ability of the liver to clear a Listeria inoculum given intravenously 1 h later. In con-
trol and treated mice an inoculum of 5 x 105 bacteria was essentially removed from
the blood within 1 h, with >90% being cleared by 15 min. Fig. 5 shows that most
of the inoculum was cleared by the liver, and that 90% of the cleared bacteria was
inactivated in N6-8 h. Treatment with 5C6 had no effect on the inactivation of Listeria
during this time. However, 5C6 treatment promoted Listeria multiplication soon after,
resulting in 10 times more bacteria in the liver at 24 h, and 3 logs more (result not
shown) at 48 h. 5C6 had no effect on bacterial multiplication in the spleen during
the first 24 h, but caused log linear growth in this organ after 24 h (results not shown) .
5C6 Treatment Renders Mice 106 Times More Susceptible to an Intradermal Listeria In-
oculum. It was evident from the histological study described above that treatment
with 5C6 prevents mice from containing bacteria at original sites of bacterial im-
plantation and of destroying bacteria therein . It was considered likely, therefore,
that the infection promoting action of 5C6 would be even more strikingly demon-
strated in mice inoculated with Listeria at a single site intradermally.
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FIGURE 4.
￿
ClearanceofListeria
from the bloodof control mice
andmice treatedwith 5C6 1 h
before intravenous inoculation
of 5 x 105 bacteria. Enumera-
tion ofbacteria in tail vein blood
at thetimesindicated showsthat
there was no significant differ-
ence betweencontrol and5C6-
treatedmice in therate at which
Listeria wasremovedfrom blood.
Results with pooled blood from
five mice per group.8-
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FIGURE 5 . Treatment with 5106
mAb 1 h before inoculating mice
intravenously with 105 Listeria had
no effect on the ability oflivermac-
rophages to destroy a large propor-
tion of the bacterial inoculum
duringthe first 8hofinfection. The
infection-promoting effect of 5106
treatment was evident in the liver,
butnot in the spleen, at 24 hof in-
fection.
It was found (Fig. 6) that normal mice are very resistant to Listeria inoculated
intradermally, in that they survived an inoculum of at least 10' bacteria. In con-
trast, mice treatedintravenously with 5106 1 h earlier all succumbed to an inoculum
of as few as 10 bacteria. Injecting IC5 intravenously 1 h earlier, however, had no
effect on the ability of mice to resist intradermally inoculated Listeria.
The reason for this striking infection-promoting action of 5106 is indicated by the
results of an experiment that measured the growth of a 5 x 103 intradermal Listeria
inoculum at the site ofinoculation, and in the draining lymph node, liver, andspleen
of control and 5106-treated mice. It canbe seen in Fig. 7 that 5106 treatment enabled
Listeria to disseminate more rapidly to the liver and spleen and to multiply in these
organs without restriction. This interference with the ability of the host to contain34
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NODE
FIGURE 6 .
￿
Evidence that treatment with 5C6, but
not IC5, mAb greatly promoted infection in mice
inoculated with Listeria intradermally. Whereas, not
even as many as 10 1 Listeria given intradermally
were lethal for control AB6 mice or IC5-treated mice
(top), as few as 10 Listeria inoculated intradermally
killed all mice treated with 5C6 mAb 1 h before in-
fection.
FIGURE 7.
￿
Consequence of 5C6
treatment on multiplication and
dissemination of5 x 103 Listeria
inoculated intradermally . 5C6
treatment 1 h before infection
caused increased multiplication
of Listeria at the site of inocula-
tion and in the draining lymph
node (axillary) . However, the
most significant infection-en-
hancing effect of5C6 treatment
was seen in its ability to promote
earlier dissemination of Listeria
to the liver and spleen, and mul-
tiplication of the organism in
these organs. Means offive mice
per group .
the organism at the site of inoculation seemed more detrimental to the host than
increased multiplication ofthe organism at the site ofinoculation andin the draining
lymph node .
Discussion
This study shows that intravenous injection ofamAb, designated 5C6, specific
for an epitope of theCR3 receptor ofmurine myelomonocytic cells prevents miceROSEN ET AL.
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from defending themselves against a sublethal, intravenous inoculum of Listeria
monocytogenes. Whereascontrol mice were able to progressively eliminate the organism
from their livers and spleens after days 2-3 of infection, 5C6-treated mice were in-
capableofexercising anycontrol over bacterialmultiplication. Consequently, alltreated
mice succumbed to overwhelming infection within 5 d. This striking infection-
promotingaction of 5C6waseven more convincingly demonstrated in mice infected
with Listeria intradermally. AB6 mice (and almost certainly other strains) arehighly
resistant to Listeria inoculated intradermally, in that they survive an inoculum of
10' at this site without any outward signs of illness. However, AB6 mice treated with
5C6 1 h before being inoculated intradermally all succumbed to as few as 10 or-
ganisms. It was apparent from the bacterial growth curves that 5C6 treatment ex-
acerbated infection, not only by reducing the ability of the host to control bacterial
multiplication at the site of inoculation, but by neutralizing its ability to retard the
dissemination of bacteria from thesite of inoculation to the liver and spleen. Conse-
quently, Listeria reached the liver and spleen much sooner, and once implanted in
these organs multiplied without restriction.
Theinfection-enhancing effect of a different anti-myelomonocytic cell mAb (IC5)
was not nearly as impressive. While the control mAb caused some increased mul-
tiplication ofintravenously inoculated Listeria, though less than that caused by 5C6,
it had no obvious effect on the ability of mice to resist infection caused by intrader-
mally inoculated Listeria. IC5 does not impair the recruitment of macrophages to
thioglycollate broth in the peritoneal cavity, and the mild exacerbation of the intra-
venously inoculated Listeria may reflect some otherimpairment ofthemacrophage-or-
ganism interaction once the macrophage has already been recruited to the infected
focus.
Ahistological examination ofthe livers of 5C6-treated mice infected intravenously
with an otherwise sublethal inoculum of Listeria revealed that increased bacterial
multiplication in this organ was associated with a failure of monocytes and other
leukocytes to accumulate at sites of bacterial implantation. Therefore, instead of
sites ofinfection being seen as macrophage-populated granulomas containing very
few visible Listeria, foci of infection in 5C6-treated mice consisted of macrophage-
free islets of infected hepatocytes in which Listeria had been multiplying extensively.
These foci of infected hepatocytes became larger and more numerous with time,
and contained enormous numbers ofbacteria. It was obvious that the organism was
spreading from one hepatocyte to the next and to distant hepatocytes via the sinu-
soids. By day3 ofinfection a majorproportion ofliverhepatocytes were overwhelm-
ingly infected with Listeria. It was apparent that 5C6 treatment had totally elimi-
nated the host's capacity to control bacterial multiplication and dissemination.
There seems to be little doubt from this study that hepatocytes, rather than mac-
rophages, are the main targets ofListeria in theliver, and that hepatocytes are devoid
of a capacity to inactivate this pathogen intracellularly. It has been shown (8), in
this connection, that Listeria is also capable of entering and rapidly multiplying in
murine fibroblasts and other cells (9, 10) in vitro, and it is reasonable to suspect
that these cells are also capable of supporting the growth ofListeria in vivo. Indeed,
rather than being able to support the growth of Listeria, as is generally assumed,
it is apparent that the cells in the mouse that predominantly kill Listeria are macro-
phages. Moreover, it has been demonstrated that normal, as well as activated mac-36
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rophages, are able to rapidly ingest and inactivate Listeria in vitro (11). The evidence
that macrophages are responsible for destroying Listeria in vivo consists ofthe demon-
stration (4)that progressive inactivation of the organism in theliver and spleen does
not begin until after day 2 of infectionwhen macrophages progressively replace neu-
trophils at foci of infection. Therefore, the absence of macrophages at sites of bac-
terial multiplication in the liver and spleen of 5C6-treated mice means that the only
host cell with a known capacity to destroyListeria is missing from sites at which anti-
Listeria resistance needs to be expressed. Thus, the infection-promoting action of
5C6 can be explained wholly on the basis of a failure of the host to focus macro-
phages at sitesofinfected hepatocytes at an early enough stage ofinfection. IfListeria
is allowedto multiply foranumber ofhoursin thesecells without restriction, a sublethal
number of Listeria is rapidly converted to a lethal number that the host is incapable
ofdestroying, even ifit eventually regains the capacity to direct macrophages to sites
of infection.
If, on the other hand, foci of infection are already populated by macrophages be-
fore 5C6 is given, the situation is entirely different, in that 5C6 causes only a tem-
porary increase in bacterial number. Presumably at this stage of infection, foci of
infected hepatocytes are already surrounded by enough macrophages to contain the
infection and destroy the organism at these sites. Whether 5C6 has the capacity to
interfere with ingestion and destruction of Listeria by monocyte-derived macrophages
at infectivefoci has yet to be determined. 5C6 does nothave the capacity to interfere
with the ability of liver Kupffer cells to clear an intravenous inoculum of Listeria
from the blood, or to interfere with the ability of Kupffer cells to destroy, in 6-8 h,
a large proportion of the Listeria load they ingest.
The infection promoting action of 5C6, then, would appear to be based on its
ability to block a crucial defence mechanism that operates between 12 and 36 h of
infection, namely, the accumulation of blood monocytesat foci of bacterial multipli-
cation. The ability of 5C6to interferewith the focusing of monocytes at foci of infec-
tion is in keeping with its ability to prevent the migration of myelomonocytic cells
from blood into peritoneal inflammatory exudates and to sites of delayed hypersen-
sitivity as described previously (5, 12).
It should be noted that exacerbation of infection by the 5C6 mAb is specific for
acute bacterial pathogens such as Listeria and that 5C6 fails to potentiate infections
of a number of different murine pathogens including West Nile virus, Plasmodium
Yoehi, and Candida albicans (Rosen, H., and S. Gordon, unpublished observations) .
It is also possible that a variety of other mAbs directed to the macrophage surface
might potentiate listeriosis, for example, by impairing phagocytic uptake or killing
without inhibiting myelomonocytic recruitment to infective foci.
Summary
Treatment of mice with arat mAb (5C6) specific for an epitope ofthe type 3 com-
plement receptor of myelomonocytic cells severely interfered with the ability of the
mice to resist infection with Listeria monocytogenes. Consequently, a sublethal infec-
tion was rapidly converted to a lethal one that resulted in death in 5 d. However,
infection was only exacerbated if 5C6 was givenearlier in infection, before mononuclear
phagocytes populated sites of Listeria implantation in the liver and spleen. If given
after day 3 ofinfection, 506 caused only a temporary increase in bacterial multipli-ROSEN ET AL.
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cation. The infection-enhancing effect of 5C6 was associated with failure of mice
to focus mononuclear phagocytes at sites of bacterial multiplication ofListeria in liver
hepatocytes and extracellularly in the spleen. This resulted in unrestricted multipli-
cation of Listeria in hepatocytes and extracellularly in the spleen. The results are
in keeping with the ability of 5C6 to inhibit the accumulation of myelomonocytic
cells in peritoneal inflammatory exudates, as revealed by a previous study (5).
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